Literature DB >> 10711855

Inhaled corticosteroid therapy in newly detected mild asthma.

P M O'Byrne1.   

Abstract

Inhaled corticosteroids are the most effective medications currently available to treat symptomatic asthma, and are free of clinically relevant unwanted effects, when used at the doses needed to provide optimal control in most patients with asthma. Inhaled corticosteroids also improve the physiological abnormalities of variable airflow obstruction and airway hyperresponsiveness that characterise asthma. Inhaled corticosteroids are also cost-beneficial when compared with other treatments, even in patients with milder asthma who are treated in primary care. For these reasons, inhaled corticosteroids are now being considered as first-line therapy for patients with regular daily asthma symptoms. Inhaled corticosteroids are, however, often not utilised until other treatments have been demonstrated not to provide optimal asthma control. Available evidence from both children and adults with asthma suggests that the benefits achieved from inhaled corticosteroids are reduced when their introduction as therapy is delayed for several years after persistent symptoms develop. For this reason, corticosteroids should be started soon after a diagnosis is made and persistent symptoms develop. It is not yet known, however, whether inhaled corticosteroids should be used in asthmatic patients who have very mild and infrequent symptoms and who have normal airway calibre most of the time. The current consensus statements do not recommend regular treatment in such patients. Airway biopsies from these asthmatic patients do show evidence of airway inflammation and structural changes; however, we do not yet know whether they lose lung function more rapidly than individuals without asthma, or whether the morbidity associated with very mild asthma warrants the use of regular treatment. This issue is being addressed in a large, multinational, placebo-controlled trial. The results of this study (available in 3 more years) will resolve this persisting question about inhaled corticosteroid use in mild asthma.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10711855     DOI: 10.2165/00003495-199958004-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  29 in total

1.  A comparative study of the effects of an inhaled corticosteroid, budesonide, and a beta 2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: a randomized, double-blind, parallel-group controlled trial.

Authors:  L A Laitinen; A Laitinen; T Haahtela
Journal:  J Allergy Clin Immunol       Date:  1992-07       Impact factor: 10.793

2.  Inflammatory cells and eosinophilic activity in asthmatics investigated by bronchoalveolar lavage. The effects of antiasthmatic treatment with budesonide or terbutaline.

Authors:  E Adelroth; L Rosenhall; S A Johansson; M Linden; P Venge
Journal:  Am Rev Respir Dis       Date:  1990-07

Review 3.  Airway inflammation and hyperresponsiveness.

Authors:  P M O'Byrne; F E Hargreave; J G Kirby
Journal:  Am Rev Respir Dis       Date:  1987-10

4.  Bronchoalveolar cell profiles of asthmatic and nonasthmatic subjects.

Authors:  J G Kirby; F E Hargreave; G J Gleich; P M O'Byrne
Journal:  Am Rev Respir Dis       Date:  1987-08

5.  Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics.

Authors:  E F Juniper; P A Kline; M A Vanzieleghem; E H Ramsdale; P M O'Byrne; F E Hargreave
Journal:  Am Rev Respir Dis       Date:  1990-10

6.  Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma.

Authors:  T Haahtela; M Järvinen; T Kava; K Kiviranta; S Koskinen; K Lehtonen; K Nikander; T Persson; O Selroos; A Sovijärvi
Journal:  N Engl J Med       Date:  1994-09-15       Impact factor: 91.245

7.  Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma.

Authors:  T Haahtela; M Järvinen; T Kava; K Kiviranta; S Koskinen; K Lehtonen; K Nikander; T Persson; K Reinikainen; O Selroos
Journal:  N Engl J Med       Date:  1991-08-08       Impact factor: 91.245

8.  Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children.

Authors:  L Agertoft; S Pedersen
Journal:  Respir Med       Date:  1994-05       Impact factor: 3.415

9.  Airway mucosal inflammation even in patients with newly diagnosed asthma.

Authors:  L A Laitinen; A Laitinen; T Haahtela
Journal:  Am Rev Respir Dis       Date:  1993-03

10.  Once-daily budesonide: 400 micrograms once daily is as effective as 200 micrograms twice daily in controlling childhood asthma. PETITE Research Group.

Authors:  L M Campbell; B Bodalia; C A Gogbashian; S D Gunn; P J Humphreys; J P Powell
Journal:  Int J Clin Pract       Date:  1998-06       Impact factor: 2.503

View more
  2 in total

1.  Allergenicity assessment of genetically-modified tobacco expressing salt tolerance cbl gene.

Authors:  Alok Kumar Verma; Sandeep Kumar; Bhushan P Chaudhari; Narendra Tuteja; Mukul Das; Premendra D Dwivedi
Journal:  Plant Foods Hum Nutr       Date:  2014-09       Impact factor: 3.921

2.  Implementing practice guidelines: a workshop on guidelines dissemination and implementation with a focus on asthma and COPD.

Authors:  Louis-Philippe Boulet; Allan Becker; Dennis Bowie; Paul Hernandez; Andrew McIvor; Michel Rouleau; Jean Bourbeau; Ian D Graham; Jo Logan; France Légaré; Thomas F Ward; Robert L Cowie; Denis Drouin; Stewart B Harris; Robyn Tamblyn; Pierre Ernst; Wan C Tan; Martyn R Partridge; Philippe Godard; Carla T Herrerias; John W Wilson; Liz Stirling; Emily-Brynn Rozitis; Nancy Garvey; Diane Lougheed; Manon Labrecque; Renata Rea; Martin C Holroyde; Danielle Fagnan; Eileen Dorval; Lisa Pogany; Alan Kaplan; Lisa Cicutto; Mary L Allen; Serge Moraca; J Mark FitzGerald; Francine Borduas
Journal:  Can Respir J       Date:  2006-03       Impact factor: 2.409

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.